drugset / Trial / NCT07115043

A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

NCT07115043

Phase 1/2 Recruiting 60 enrolled AstraZeneca
Non-randomizedParallel-groupOpen-labelTreatment

Summary

A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

Timeline

Start
2025-07-29
Primary completion
2029-10-02
Completion
2029-10-02

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD6750 Unknown Intravenous
Subject Rilvegostomig Other / unclassified Intravenous